Skin dendritic cells in murine cutaneous leishmaniasis

M C Udey1, E von Stebut, S Mendez

  • 1Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1908, USA.

Immunobiology
|February 16, 2002
PubMed

Insights

Murine models of Leishmania major infection reveal that T-helper (Th) cell-derived type I cytokines are crucial for macrophage activation and parasite control. Dendritic cells, not macrophages, initiate the immune response to Leishmania major.

Area of Science:

  • Immunology
  • Parasitology
  • Vaccine Development

Background:

  • Leishmania major infection causes cutaneous leishmaniasis.
  • Understanding its immunopathogenesis informs human disease progression and vaccine design.
  • Murine models are key to studying Leishmania major infection.

Purpose of the Study:

  • To investigate the immunopathogenesis of Leishmania major-induced murine cutaneous leishmaniasis.
  • To understand the role of T-helper (Th) cell cytokines and antigen-presenting cells in parasite control.
  • To compare findings from high-dose and low-dose parasite inoculation models.

Main Methods:

  • Utilizing murine models of cutaneous leishmaniasis.
  • Infecting mice with varying doses of Leishmania major parasites (supraphysiologic and physiologic).
  • Analyzing macrophage activation, nitric oxide production, and T-cell priming by dendritic cells.

Main Results:

  • Th-derived type I cytokines are essential for macrophage activation and nitric oxide production, crucial for parasite control.
  • Dendritic cells, not macrophages, are primarily responsible for Leishmania major-specific Th priming.
  • Low-dose inoculation models confirm high-dose findings but reveal differences in dendritic cell recruitment and parasite acquisition.

Conclusions:

  • T-helper cell-derived type I cytokines and macrophage nitric oxide production are critical for controlling Leishmania major.
  • Dendritic cells play a pivotal role in initiating the adaptive immune response to Leishmania major.
  • Low-dose inoculation models offer unique insights into dendritic cell function and immune responses in cutaneous leishmaniasis.